In a report released today, Mark Massaro from Canaccord Genuity maintained a Hold rating on Hologic (NASDAQ: HOLX), with a price target of $41. The company’s shares opened today at $41.03.
According to TipRanks.com, Massaro is a top 100 analyst with an average return of 19.9% and a 63.8% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Idexx Laboratories, and Exact Sciences.
Currently, the analyst consensus on Hologic is a Moderate Buy with an average price target of $45.50, representing a 10.9% upside. In a report issued on September 13, Merrill Lynch also downgraded the stock to Hold with a $42 price target.
.
See today’s analyst top recommended stocks >>
Based on Hologic’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $824 million and net profit of $113 million. In comparison, last year the company had a net profit of $59.5 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health.
